Pediatric ALLNCT05645133
QPlus Pediatric Reference Interval
An observational study of Pediatric ALL and Healthy, run by HemoSonics LLC at 1 site in United States.
Trial summary
Evaluation of coagulation results reported by the Qplus Quantra System to determine pediatric reference range intervals. Read more about this study
- Who is it for?
- Ages Up to 17 yearsHealthy volunteers can take part
- Conditions the study is for
- Pediatric ALL, Healthy
- What is being tested?
- Diagnostic Test
- Type of treatment
- Medical device
- How many people
- 93 participants
- Where
- 1 siteUnited States
- Study dates
- 27 Feb 2023to 10 Jun 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 17 years
- All sexes
- Healthy volunteers accepted
- Child
Study population: Pediatric patients with normal coagulation function who have been scheduled to undergo a procedure and blood sampling access has been established. All genders, racial and ethnic profiles will be described.
Who may be able to join
- <18yrs
- Scheduled for procedure requiring anesthesia
- Access to blood sampling
- Consented
Who cannot join
- >18yrs of age
- pre-term babies
- patients with know hematological disorders
- Difficult to obtain blood sampling
- Has received a blood product transfusion within the last 24hrs.
- Legal guardian unwilling to consent
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Evaluation of a Pediatric Reference Interval Using QPLUS System
Evaluation of coagulation results reported by the Qplus Quantra System to determine pediatric reference range intervals.
Read the detailed description
Single center observational study of the pediatric patient population (< 18yrs) with normal coagulation function to determine the reference range interval for the clotting parameters reported by the Quantra QPlus system.
- Conditions
- Pediatric ALL, Healthy
- Being tested
- Diagnostic Test
- Keywords
- QPlus, Quantra, Pediatric, Reference Range
- Medical subject headings
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Diagnostic TestDevice
Also called Point of Care test, Quantra
Diagnostic device to monitor coagulation properties of a whole blood sample at the point of care
What is being measured
The primary outcome is the main question the study is designed to answer.
Reference range interval for measurement of clot time (CT) parameter
Reference range interval determined in this study will serve as the reference for CT results in this particular population
Measured: Baseline, after access placement before any procedures
Reference range interval for measurement of clot time (CTH) parameter
Reference range interval determined in this study will serve as the reference for CTH results in this particular population
Measured: Baseline, after access placement before any procedures
Reference range interval for measurement of clot stiffness (CS) parameter
Reference range interval determined in this study will serve as the reference for CS results in this particular population
Measured: Baseline, after access placement before any procedures
Reference range interval for measurement of Fibrinogen Contribution to clot stiffness (FCS) parameter
Reference range interval determined in this study will serve as the reference for FCS results in this particular population
Measured: Baseline, after access placement before any procedures
Reference range interval for measurement of Platelet Contribution to clot stiffness (PCS) parameter
Reference range interval determined in this study will serve as the reference for PCS results in this particular population
Measured: Baseline, after access placement before any procedures
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Dec 2022
- Study start27 Feb 2023
- Primary completion1 Jun 2023
- Study completion10 Jun 2023
Why it stopped: PI relocated to another institution
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pediatric ALLStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 93 participants (actual)
Sponsor and investigators
- Lead sponsor
- HemoSonics LLC
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Christopher Tirotta, MD, Principal investigator, Nicklaus Childrens
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05645133
- Sponsor's protocol ID
- IIS-005
- Status last verified
- Jun 2023
- First submitted
- 1 Dec 2022
- Last updated
- 15 Jun 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Jun 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of a Pediatric Reference Interval Using QPLUS System
- ClinicalTrials.gov ID
- NCT05645133
- Acronym / sponsor ID
- IIS-005
- Conditions
- Pediatric ALL, Healthy
- Keywords
- QPlus, Quantra, Pediatric, Reference Range
- Study type
- Observational
- Recruitment status
- TerminatedReason stopped: PI relocated to another institution
- Enrolment
- 93 participants (actual)
- Lead sponsor
- HemoSonics LLCIndustry (pharma, biotech, devices)
- Study start
- 27 Feb 2023 (actual)
- Primary completion
- 1 Jun 2023 (actual)
- Study completion
- 10 Jun 2023 (actual)
- First posted
- 9 Dec 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Evaluation of coagulation results reported by the Qplus Quantra System to determine pediatric reference range intervals.
Detailed description
Single center observational study of the pediatric patient population (< 18yrs) with normal coagulation function to determine the reference range interval for the clotting parameters reported by the Quantra QPlus system.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- Up to 17 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
- Study population
- Pediatric patients with normal coagulation function who have been scheduled to undergo a procedure and blood sampling access has been established. All genders, racial and ethnic profiles will be described.
Key inclusion criteria (4 listed)
- <18yrs
- Scheduled for procedure requiring anesthesia
- Access to blood sampling
- Consented
Key exclusion criteria (6 listed)
- >18yrs of age
- pre-term babies
- patients with know hematological disorders
- Difficult to obtain blood sampling
- Has received a blood product transfusion within the last 24hrs.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Diagnostic TestAlso: Point of Care test, QuantraDiagnostic device to monitor coagulation properties of a whole blood sample at the point of care | Device | – |
Primary outcome
Reference range interval for measurement of clot time (CT) parameter
Time frame: Baseline, after access placement before any procedures
Reference range interval determined in this study will serve as the reference for CT results in this particular population
Reference range interval for measurement of clot time (CTH) parameter
Time frame: Baseline, after access placement before any procedures
Reference range interval determined in this study will serve as the reference for CTH results in this particular population
Reference range interval for measurement of clot stiffness (CS) parameter
Time frame: Baseline, after access placement before any procedures
Reference range interval determined in this study will serve as the reference for CS results in this particular population
Reference range interval for measurement of Fibrinogen Contribution to clot stiffness (FCS) parameter
Time frame: Baseline, after access placement before any procedures
Reference range interval determined in this study will serve as the reference for FCS results in this particular population
Reference range interval for measurement of Platelet Contribution to clot stiffness (PCS) parameter
Time frame: Baseline, after access placement before any procedures
Reference range interval determined in this study will serve as the reference for PCS results in this particular population
Results and safety
The study was stopped early (reason given: PI relocated to another institution). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jun 2023.
- Individual participant dataSharing planned: No
Related trials for Pediatric ALL
Not yet recruitingPhase 1/2
A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia
Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Not yet recruiting
The Contribution of Accelerated Recovery (mERAS) Approach to Postoperative Recovery in Pediatric Laparoscopic Surgery Cases
mERAS Intervention, The ASA (American Society of Anesthesiologists) Score
Recruiting
Amnioinfusion's Protective Effects on Respiratory and Longitudinal Pediatric Outcomes After Intrapartum Meconium Exposure
Neonatal Respiratory Distress Related Conditions, Meconium
Not yet recruitingObservational study
Multimodal Mechanical, Tissue, Architectural, and Histological Evaluation of the Bone and Sutures of the Parietal Bone in an Infant With Craniosynostosis.
Craniostenosis
Recruiting
Evaluating Long-term Use of a Pediatric Robotic Exoskeleton (P.REX/Agilik) to Improve Gait in Children With Movement Disorders
Cerebral Palsy, Muscular Dystrophy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Christopher Tirotta, MD principal investigator
Nicklaus Childrens
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pediatric ALL and Healthy, run by HemoSonics LLC at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 15 Jun 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: PI relocated to another institution). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Reference range interval for measurement of clot time (CT) parameter (time frame: Baseline, after access placement before any procedures). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jun 2023.